Enlivex Therapeutics Ltd
NASDAQ:ENLV
Enlivex Therapeutics Ltd
Interest Income Expense
Enlivex Therapeutics Ltd
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Interest Income Expense
$341k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Interest Income Expense
$503k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
NASDAQ:KMDA
|
Interest Income Expense
-$85k
|
CAGR 3-Years
58%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
30%
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Interest Income Expense
-$9.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Interest Income Expense
$31k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Interest Income Expense
₪1.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
See Also
What is Enlivex Therapeutics Ltd's Interest Income Expense?
Interest Income Expense
341k
USD
Based on the financial report for Dec 31, 2023, Enlivex Therapeutics Ltd's Interest Income Expense amounts to 341k USD.